Stealth BioTherapeutics studies elamipretide in Phase II/III trial for Barth syndrome

US-based Stealth BioTherapeutics has started a Phase II/III TAZPOWER clinical trial to investigate its product candidate elamipretide to treat patients with Barth syndrome caused due to TAZ gene mutations.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news